Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases (2021 - 2025)

Historic Current Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $583000.0.

  • ARS Pharmaceuticals' Current Leases rose 47156.86% to $583000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $583000.0, marking a year-over-year increase of 47156.86%. This contributed to the annual value of $42000.0 for FY2024, which is 8227.85% down from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Current Leases stood at $583000.0, which was up 47156.86% from $589000.0 recorded in Q2 2025.
  • ARS Pharmaceuticals' Current Leases' 5-year high stood at $1.1 million during Q1 2022, with a 5-year trough of $42000.0 in Q4 2024.
  • Moreover, its 5-year median value for Current Leases was $233000.0 (2023), whereas its average is $435315.8.
  • Per our database at Business Quant, ARS Pharmaceuticals' Current Leases crashed by 8227.85% in 2024 and then skyrocketed by 47156.86% in 2025.
  • ARS Pharmaceuticals' Current Leases (Quarter) stood at $144000.0 in 2021, then soared by 59.72% to $230000.0 in 2022, then grew by 3.04% to $237000.0 in 2023, then tumbled by 82.28% to $42000.0 in 2024, then skyrocketed by 1288.1% to $583000.0 in 2025.
  • Its Current Leases was $583000.0 in Q3 2025, compared to $589000.0 in Q2 2025 and $73000.0 in Q1 2025.